Free Trial
NASDAQ:LPTX

Leap Therapeutics Q1 2025 Earnings Report

Leap Therapeutics logo
$0.28 -0.03 (-9.35%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$0.28 -0.01 (-1.82%)
As of 06/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Leap Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Leap Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Leap Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Leap Therapeutics Earnings Headlines

When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Leap Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Leap Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Leap Therapeutics and other key companies, straight to your email.

About Leap Therapeutics

Leap Therapeutics (NASDAQ:LPTX), a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

View Leap Therapeutics Profile

More Earnings Resources from MarketBeat